Advertisement
U.S. markets open in 5 hours 24 minutes
  • S&P Futures

    5,304.75
    -3.50 (-0.07%)
     
  • Dow Futures

    40,104.00
    -40.00 (-0.10%)
     
  • Nasdaq Futures

    18,504.00
    +0.25 (+0.00%)
     
  • Russell 2000 Futures

    2,135.30
    -3.10 (-0.14%)
     
  • Crude Oil

    81.76
    +0.41 (+0.50%)
     
  • Gold

    2,214.40
    +1.70 (+0.08%)
     
  • Silver

    24.61
    -0.14 (-0.55%)
     
  • EUR/USD

    1.0797
    -0.0033 (-0.30%)
     
  • 10-Yr Bond

    4.1960
    0.0000 (0.00%)
     
  • Vix

    12.95
    +0.17 (+1.33%)
     
  • GBP/USD

    1.2612
    -0.0026 (-0.20%)
     
  • USD/JPY

    151.4240
    +0.1780 (+0.12%)
     
  • Bitcoin USD

    70,388.69
    +544.24 (+0.78%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,931.98
    0.00 (0.00%)
     
  • Nikkei 225

    40,168.07
    -594.66 (-1.46%)
     

I Ran A Stock Scan For Earnings Growth And Cross Country Healthcare (NASDAQ:CCRN) Passed With Ease

Some have more dollars than sense, they say, so even companies that have no revenue, no profit, and a record of falling short, can easily find investors. And in their study titled Who Falls Prey to the Wolf of Wall Street?' Leuz et. al. found that it is 'quite common' for investors to lose money by buying into 'pump and dump' schemes.

In the age of tech-stock blue-sky investing, my choice may seem old fashioned; I still prefer profitable companies like Cross Country Healthcare (NASDAQ:CCRN). While that doesn't make the shares worth buying at any price, you can't deny that successful capitalism requires profit, eventually. While a well funded company may sustain losses for years, unless its owners have an endless appetite for subsidizing the customer, it will need to generate a profit eventually, or else breathe its last breath.

See our latest analysis for Cross Country Healthcare

How Fast Is Cross Country Healthcare Growing Its Earnings Per Share?

In business, though not in life, profits are a key measure of success; and share prices tend to reflect earnings per share (EPS). So like the hint of a smile on a face that I love, growing EPS generally makes me look twice. You can imagine, then, that it almost knocked my socks off when I realized that Cross Country Healthcare grew its EPS from US$0.24 to US$4.57, in one short year. Even though that growth rate is unlikely to be repeated, that looks like a breakout improvement. But the key is discerning whether something profound has changed, or if this is a just a one-off boost.

I like to see top-line growth as an indication that growth is sustainable, and I look for a high earnings before interest and taxation (EBIT) margin to point to a competitive moat (though some companies with low margins also have moats). Cross Country Healthcare shareholders can take confidence from the fact that EBIT margins are up from 4.0% to 10%, and revenue is growing. That's great to see, on both counts.

The chart below shows how the company's bottom and top lines have progressed over time. To see the actual numbers, click on the chart.

earnings-and-revenue-history
earnings-and-revenue-history

Fortunately, we've got access to analyst forecasts of Cross Country Healthcare's future profits. You can do your own forecasts without looking, or you can take a peek at what the professionals are predicting.

Are Cross Country Healthcare Insiders Aligned With All Shareholders?

It makes me feel more secure owning shares in a company if insiders also own shares, thusly more closely aligning our interests. As a result, I'm encouraged by the fact that insiders own Cross Country Healthcare shares worth a considerable sum. Indeed, they hold US$34m worth of its stock. That shows significant buy-in, and may indicate conviction in the business strategy. That amounts to 5.3% of the company, demonstrating a degree of high-level alignment with shareholders.

It's good to see that insiders are invested in the company, but are remuneration levels reasonable? Well, based on the CEO pay, I'd say they are indeed. I discovered that the median total compensation for the CEOs of companies like Cross Country Healthcare with market caps between US$400m and US$1.6b is about US$4.0m.

The Cross Country Healthcare CEO received total compensation of just US$1.3m in the year to . That's clearly well below average, so at a glance, that arrangement seems generous to shareholders, and points to a modest remuneration culture. CEO compensation is hardly the most important aspect of a company to consider, but when its reasonable that does give me a little more confidence that leadership are looking out for shareholder interests. It can also be a sign of good governance, more generally.

Is Cross Country Healthcare Worth Keeping An Eye On?

Cross Country Healthcare's earnings have taken off like any random crypto-currency did, back in 2017. The sweetener is that insiders have a mountain of stock, and the CEO remuneration is quite reasonable. The sharp increase in earnings could signal good business momentum. Big growth can make big winners, so I do think Cross Country Healthcare is worth considering carefully. You should always think about risks though. Case in point, we've spotted 5 warning signs for Cross Country Healthcare you should be aware of, and 3 of them make us uncomfortable.

Although Cross Country Healthcare certainly looks good to me, I would like it more if insiders were buying up shares. If you like to see insider buying, too, then this free list of growing companies that insiders are buying, could be exactly what you're looking for.

Please note the insider transactions discussed in this article refer to reportable transactions in the relevant jurisdiction.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Advertisement